Clinical trial
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk…
NCT00469729 · Gamida Cell -Teva Joint Venture Ltd., Other · Completed
Key facts
| NCT number | NCT00469729 |
|---|---|
| Title | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy |
| Official title | A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy |
| Acronym | ExCell |
| Lead sponsor | Gamida Cell -Teva Joint Venture Ltd., Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Hematologic Malignancies, Acute Myeloid Leukemia, Lymphoid Leukemia, Chronic Myeloid Leukemia, Hodgkin's Disease, Non-Hodgkin's Lymphoma, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | StemEx® |
| Enrollment | 101 |
| Start date | Oct 1, 2007 |
| Primary completion | Feb 1, 2013 |
| Completion | Jun 1, 2015 |
| First posted | May 4, 2007 |
| Last update posted | Jul 10, 2015 |
| Countries | Hungary, Israel, Italy, Spain, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: